Objective To detect the expression levels of geminin and cdt1 in bone marrow of patients with acute myeloid leukemia(AML),and investigate their relationship with the pathogenesis and prognosis of this condition. Methods Using SYBR Green real-time quantitative reverse transcription polymerase chain reaction(SYBR-RT-PCR),the expressions of geminin and cdt1 mRNA were detected in 47 AML patients at different phases,including 25 initially-treated,16 complete-remission and six non-remission or relapsed.A follow-up of six months was done in those initially treated. Results The expression levels of geminin and cdt1 in initially-treated,non-remission or relapsed patients were higher than that in the controls and complete-remission,the differences being significant(H=4.95,3.22;Z=2.67-4.95;P0.01);the differences of geminin and cdt1 between the complete-remission and the controls were not significant(P0.05).In AML,the expressions of geminin and cdt1 in bone marrow cells were positively correlated(r=0.59,P0.01),and a positive correlation was noted of both the two expressions in initially-treated,remission and relapsed groups(r=0.49-0.87,P0.05).A follow-up of six months was conducted in 25 initially-treated patients,six of them died.The expression of geminin in those who died was higher than that who survived,the difference being significant(t=2.16,P0.05),but the difference of cdt1 expression between the two groups was not significant(t=0.61,P0.05). Conclusion Geminin and cdt1 expressions may be correlated with the course of the disease,and the high expression of geminin in initially-treated patients is likely to be a poorly prognostic prediction of AML.

OBJECTIVE:To explore the expression and correlation of MK and VEGF gene in acute leukemia(AL),and evaluate their relationship with angiogenesis and prognosis.METHODS:The expression level of MK and VEGF in 95 AL patients in different phase were detected by Taqman real-time fluorescent quantitative RT-PCR.RESULTS: The expressions level of MK and VEGF in acute myelogenous leukemia(AML) and acute lymphoblastic leukemia(ALL) were significantly higher than those in control group(P=0.000 0);The expression level of MK and VEGF in untreated/relapsed groups was significantly higher than that in control/remission groups(P0.01);The expression level of MK and VEGF in remission group was also significantly higher than that in control group(P0.01).Linear correlation was observed between the level of MK and VEGF in relapsed group(r=0.526,P0.05).In remission group,MK had linear relationship with VEGF and the ratio of the blast cell in bone marrow(r=0.673,P0.01;r=0.468,P0.01),but in untreated/control groups,there was no linear relationship among MK,VEGF level and the ratio of the blast cell in bone marrow.CONCLUSIONS: The high expressions of MK and VEGF are correlated with angiogenesis and prognosis in AL,and there is synergistic effect between MK and VEGF.Monitoring MK and VEGF can be used to guide the treatment and to estimate prognosis.

The purpose of this study was to explore the expressions of midkine (MK) and vascular endothelial growth factor (VEGF) in multiple myeloma (MM), and to evaluate their relation with angiogenesis and prognosis. The expression levels of MK and VEGF in bone marrow mononuclear cells of 31 MM patients in different stages and 20 controls were detected by real-time fluorescent quantitative RT-PCR. The results showed that the MM patients had significantly higher MK and VEGF expression level than control group (p < 0.05, p < 0.01), and there was a linear relationship between MK and VEGF (r = 0.692, p < 0.01); The expression levels of MK and VEGF in stage III was significantly higher than those in stage I and stage II (p < 0.05, p < 0.01), but there was no difference between stage I and stage II (p > 0.05); MK and VEGF levels were significantly decreased in MM patients after treatment than those before treatment (p < 0.05, p < 0.01). It is concluded that the high expression of MK and VEGF is correlated with angiogenesis and prognosis of MM, and there is synergistic effect between MK and VEGF. It is supposed that the monitoring MK and VEGF expression levels may contribute to guide the treatment and estimate prognosis for MM.

中期因子(Midkine,MK)是1988年发现的一种新的肝素结合生长因子.MK是一种可分泌蛋白,成熟的MK分子由121个氨基酸残基组成,富含碱性氨基酸及半胱氨基酸.因起初在孕中期小鼠胚胎肾脏发现其大量表达而得名,是妊娠中期(midgestation)和肾脏(kidney)的缩写.随后又发现了一种可与肝素结合的生长因子,称为多效生长因子(Pleiotrophin,PTN).MK和PTN与既往已知的肝素结合生长因子在结构上明显不同,二者组成了一种新的蛋白质家族.